2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 99

Academic and Non-Academic Rheumatology: Practice Trends and Common Barriers to Practice from the 2015 ACR/ARHP Workforce Study Survey
Abstract Number: 1424

Acceptability of a Connected Activity Tracker in 92 Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (axSpA): A 3-Months Study
Abstract Number: 1414

Access to an Active, Interactive Self-Assessment e-Health Platform Improves Patient-Physician Communication in Rheumatoid Arthritis: Results of a Randomized Controlled Trial Including 320 Patients over 1 Year
Abstract Number: 1248

Access to Care: The Patient Perspective from the 2015 ACR/ARHP Workforce Study
Abstract Number: 1790

Accrual of Disease Comorbidities over 8 Years in a Multicentre Inception SLE Cohort
Abstract Number: 218

Accuracy of Humasens-Plus Point-of-Care Uric Acid Meter Using Capillary Blood Obtained By Fingertip Puncture
Abstract Number: 2524

Achievement of Imaging Remission Among Patients with Rheumatoid Arthritis in Clinical Remission and Their Characteristics
Abstract Number: 582

ACPA Induce Pathogenic Cytokines Expression in PBMC of ACPA+-RA Patients and Inhibition of Its Effect By Cit-ME a Synthetic Citrullinated Peptide
Abstract Number: 1923

Activated Partial Thromboplastin Time Reflects Disease Activity in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Abstract Number: 1860

Activating Transcription Factor 3 – a New Linkage Between Vasculopathy and Organ Fibrosis in Systemic Sclerosis
Abstract Number: 2935

Activation Status of Mucosal-Associated Invariant T Cells Sensitively Reflects Disease Activity of Systemic Lupus Erythematosus
Abstract Number: 593

Adalimumab (HUMIRA) Halts Radiographic Progression and Reduces Disease Activity in Patients with a Poor Initial Response to Methotrexate
Abstract Number: 2947

Adalimumab Versus Infliximab in Cystoid Macular Edema of Uveitis Associated to BehçEt Disease. Multicenter Study of 34 Patients
Abstract Number: 1101

Adalimumab:TNF Complexes Induce a Divergent Proteomic Profile in Human Osteoclast Precursors to That Resembling a Monocytic Cell
Abstract Number: 453

Adaptation and Validation the Systemic Sclerosis Quality of Life Questionnaire into Spanish Using Rasch Analysis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].